Diuretic Management with Torsemide

Initial Dosing and Titration

The American College of Cardiology recommends starting torsemide at a dose of 10-20 mg once daily for heart failure-associated edema and 20 mg for renal-associated edema, and titrating upward by approximately doubling the dose only if the diuretic response is inadequate after several days of consistent use 1
Torsemide has a prolonged duration of action of 12-16 hours, which means steady-state diuretic effect takes several days to establish after restarting therapy 1

The goal of diuretic therapy is progressive weight loss of 0.5-1.0 kg daily once diuresis is established, not immediate resolution of edema 2
Daily weights are the primary guide for dose adjustments, and patients should weigh themselves at the same time each morning 2
Electrolytes, renal function, and blood pressure should be checked within 1-2 weeks of restarting therapy or any dose change 2

Strict sodium restriction to ≤2 g daily is essential to enhance diuretic response 2
Consider fluid restriction to 2 liters daily if edema persists despite sodium restriction and adequate diuretic dosing 2

If diuretic resistance occurs, consider adding a thiazide-type diuretic, such as metolazone 2.5-10 mg once daily, for sequential nephron blockade 1
Combination diuretic therapy markedly increases the risk of severe electrolyte depletion and requires intensive monitoring 2

In patients with heart failure, a weight gain of approximately 3 lb (≈1.4 kg) together with new objective signs of congestion (e.g., peripheral edema, elevated jugular venous pressure, pulmonary crackles) indicates inadequate diuresis on torsemide 10 mg and supports increasing the dose to 20 mg daily. 3

The American College of Cardiology advises that systolic blood pressure must be ≥ 90–100 mm Hg before a diuretic dose is increased. 3
Severe renal impairment—defined as serum creatinine > 2.5 mg/dL or estimated glomerular filtration rate < 30 mL/min/1.73 m²—requires caution; normal renal function permits dose escalation. 3
Absolute contraindications include severe hyponatremia (serum sodium < 120–125 mmol/L) or severe hypokalemia (serum potassium < 3.0 mmol/L); their absence allows the dose increase. 3

Persistent volume overload should not be delayed because of mild azotemia or modest blood‑pressure reductions, as untreated congestion worsens outcomes and limits the efficacy of other heart‑failure therapies (e.g., ACE inhibitors, beta‑blockers). 3
A transient increase in serum creatinine up to 0.3 mg/dL should not lead to discontinuation of diuretics if the patient remains asymptomatic and volume status improves. 3